About this trial
This study aims to evaluate the burden and phenotypic spectrum of periodontal disease in patients with rare kidney disorders (such as Alport syndrome, Fabry disease, and tuberous sclerosis complex) and systemic lupus erythematosus (SLE), compared with chronic kidney disease (CKD) controls and population controls.
This is a cross-sectional, case-control observational study. Participants will undergo a single structured evaluation including a full-mouth periodontal examination, a clinical questionnaire, and collection of relevant clinical and nephrological data.
The primary objective is to compare the prevalence of periodontitis across study groups. Secondary objectives include characterization of periodontal disease severity, prevalence of gingivitis and xerostomia, and identification of disease-specific oral phenotypes.
Exploratory analyses will assess associations between periodontal disease and clinical variables such as kidney function, proteinuria, and immunosuppressive exposure.
Eligibility criteria
Qualifiers
Age ≥18 years
Ability to provide written informed consent
At least 10 natural teeth present
Alport syndrome (genetically or clinically confirmed)
Disqualifiers
Periodontal treatment within the last 6 months
Antibiotic therapy within the last 4 weeks
Pregnancy
Conditions precluding periodontal examination
Trial design
Treatments tested in this trial
- Observational assessment
Treatment groups
6
Treatment groupsSee each treatment group below.
Locations
1Sponsors and collaborators
Stefan Lujinschi
Lead sponsor
Institutul Clinic Fundeni
Sponsor institution
Institutul Clinic Fundeni
Collaborator